Meiji Seika Pharma Partners with MBC BioLabs to Accelerate Drug Discovery Innovation
核心洞察
Meiji Seika Pharma (搜索) has entered into a strategic partnership with MBC BioLabs (搜索), a California-based biotech incubator, to strengthen global innovation in drug discovery.
The collaboration will advance Meiji's open-innovation initiatives in priority therapeutic areas including infectious diseases (搜索), hematologic diseases (搜索), and immune-inflammatory diseases (搜索).
MBC BioLabs (搜索) has supported over 500 companies since 2013, helping bring 176 programs to clinical trials and raising over $20 billion in funding.
Japanese pharmaceutical company Meiji Seika Pharma (搜索) Co., Ltd. has announced a strategic partnership with MBC BioLabs (搜索), a premier life science incubator based in California's San Francisco Bay Area, to strengthen global innovation in drug discovery and advance its open-innovation initiatives.
Partnership Objectives and Strategic Focus
The collaboration is designed to accelerate Meiji Seika Pharma (搜索)'s research and development efforts in three priority therapeutic areas: infectious diseases (搜索), hematologic diseases (搜索), and immune-inflammatory diseases (搜索). Through this partnership, the company aims to engage with biotech entrepreneurs and the startup community at MBC BioLabs (搜索) to discover innovative drug discovery seeds and accelerate external collaborations.
"We aim to energize our drug discovery research by drawing new ideas from global innovation activities and deepening collaboration with innovation hubs in Japan and overseas," said Takeshi Naruse, Managing Executive Officer and Head of R&D at Meiji Seika Pharma (搜索). "Partnering with MBC BioLabs (搜索), which has a proven track record of identifying numerous startups and guiding them toward commercialization, represents a major step forward in these efforts."
MBC BioLabs' Track Record and Infrastructure
MBC BioLabs (搜索) provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization.
Since opening in 2013, MBC BioLabs (搜索) has demonstrated significant impact in the biotechnology ecosystem, helping launch and grow over 500 companies. These companies have achieved notable milestones, bringing 176 programs to clinical trials, producing 17 approved diagnostics, bringing 135 products to market, and raising over $20 billion in total funding.
"MBC BioLabs (搜索) is excited to partner with Meiji Seika Pharma (搜索) to empower entrepreneurs and help bring Meiji's innovations to the U.S. biotechnology ecosystem," said Flavia Nachbar, Director of Alliances at MBC BioLabs. "This collaboration reflects our shared belief that bold science, backed by the right resources and relationships, can transform human health around the world."
Meiji Seika Pharma's Innovation Strategy
Meiji Seika Pharma (搜索) has been a significant player in pharmaceutical development since launching penicillin (搜索) in 1946. The company has built expertise in providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases (搜索), therapeutics for central nervous system diseases (搜索), and generic drugs.
To address unmet medical needs, the company is committed to creating next-generation therapies by focusing its R&D on priority areas and actively leveraging open innovation. This partnership with MBC BioLabs (搜索) represents a key component of this strategy, connecting the company with the vibrant biotech innovation ecosystem in the San Francisco Bay Area.